BIO Seeks Weight-Of-Evidence Standard For Drug Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug reviewers should be able to consider efficacy evidence beyond double-blind, randomized controlled trials, the group says in proposals to stimulate biomedical innovation.
You may also be interested in...
FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.
FDA Approval Standards Need To Be Relaxed, Venture Capitalists Say
FDA should accept “a reasonable likelihood of patient benefit” as the appropriate standard for approving therapies for unmet medical needs, the National Venture Capital Association and its Medical Innovation & Competitiveness Coalition contend.
Woodcock Defends Speed Of FDA Reviews, Cites 20 Approvals In First Half Of 2011
As House begins hearings on PDUFA V, industry and venture capitalists say agency policies pre-NDA submission slow drug development.